KVV E-Modules - Injectable Pre-formulation Sciences: Case Studies in Solubility, Stability, Sterility, and Compatibility for Parenteral Drug Product

Quadrant -I (Video)

Injectable Pre-formulation Sciences: Case Studies in Solubility, Stability, Sterility, and Compatibility for Parenteral Drug Product

Quadrant - II (Study Material)

1. Injectable Pre-formulation Sciences: Case Studies in Solubility, Stability, Sterility, and Compatibility for Parenteral Drug Product

View File

Quadrant - III (Assignments)

1. Injectable Pre-formulation Sciences: Case Studies in Solubility, Stability, Sterility, and Compatibility for Parenteral Drug Product

Discuss the role of pre-formulation studies in the development of injectable drug products. Explain the importance of solubility, stability, sterility, and compatibility with suitable examples.

Quadrant - IV (MCQs)

7. Which of the following is a critical pre-formulation parameter for injectable products?

A: Color B: Color C: Sterility D: Packaging design

1. Poor aqueous solubility of paclitaxel was addressed using which formulation strategy?

A: Liposomes B: Cremophor EL and ethanol C: Cyclodextrins D: Polymer coating

2. What was the major drawback of paclitaxel formulation with Cremophor EL?

A: Low efficacy B: High cost C: Hypersensitivity reactions D: Rapid degradation

3. What was the major drawback of paclitaxel formulation with Cremophor EL?

A: Low efficacy B: High cost C: Hypersensitivity reactions D: Rapid degradation

4. What was the major drawback of paclitaxel formulation with Cremophor EL?

A: Low efficacy B: High cost C: Hypersensitivity reactions D: Rapid degradation

5. Amphotericin B conventional formulation showed which type of instability?

A: Chemical degradation B: Aggregation instability C: Photodegradation D: Hydrolysis

6. What is the major consequence of sterility failure in injectable products?

A: Change in color B: Reduced solubility C: Severe infections and sepsis D: Increased viscosity

8. Ceftriaxone should not be mixed with calcium-containing solutions due to:

A: Color change B: Increased potency C: Formation of insoluble precipitates D: Increased solubility

10. Which of the following is NOT a pre-formulation parameter?

A: Solubility B: Stability C: Sterility D: Marketing strategy

9. Which of the following best describes compatibility studies?

A: Determination of taste B: Study of drug interactions with excipients and containers C: Stability under temperature D: Solubility measurement

Validation Certificates

1. Checking Report

View File

Module Views - 43